AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus Announces Appointment of Stratos Davlos as Chief Technology Officer (CTO) and Senior Vice President
Hoboken, New Jersey, September 16, 2019- Innoplexus Inc., a subsidiary of Innoplexus AG, announced today the appointment of Stratos Davlos as Chief Technology Officer (CTO) and Senior Vice President. Mr. Davlos is a highly accomplished artificial intelligence and machine learning executive with over 20 years of leadership experience.
Prior to joining Innoplexus, Mr. Davlos was the Vice President of Watson, AI & Engineering at IBM. His AI-focused career spans many years of executive technology management and development at among others Reliance Jio and Apple. Mr. Davlos holds many innovations, patents and has received many honors and awards.
“We are very excited to welcome Stratos to Innoplexus at such an important time as we roll out our AI-powered platform for Drug Discovery and Development for various industry stakeholders. His expertise and extensive experience will help us accelerate scaling our AI,“ said Dr. Gunjan Bhardwaj, Founder, and CEO of Innoplexus.
Stratos will be based in California in his global role and will build an Innoplexus Research Lab in the Valley. “I am excited to be a part of a purpose-driven company and continue to innovate with AI for effective and efficient drug discovery. Together with Innoplexus, we will put a dent in the universe for the service of humanity “, said Stratos.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…